Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$151.22 USD
-1.11 (-0.73%)
Updated May 6, 2024 04:00 PM ET
After-Market: $154.99 +3.77 (2.49%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 41 - 60 ( 406 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
APOLLO-B 18-Month Results Bolster RNAi Prospects in ATTR Amyloidosis With Cardiomyopathy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; AMVUTTRA shines; RNAi Moves Into CNS; 2023 Product Sales Guidance Maintained
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial Validation of RNAi in the CNS Emerges With ALNAPP; FDA Clinical Hold Appears Addressable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Positive Momentum Ahead of Key Catalysts on ATTR Amyloidosis, HBV, and Hypertension Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
RNAi Pipeline Firing on All Cylinders; Multiple Datasets in Potential Blockbuster Programs Expected in 2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Executing Well in a Challenging Environment; Lowering PT to $415 on Stargardt Delay
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
More Good News on TTR Franchise Emerges With Compelling Subgroup Data From Phase 3 APOLLO-B Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Positive Data Emerges on Key Programs Including ONPATTRO in ATTR and Cemdisiran in IgAN; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department